Arcturus Therapeutics Share Price Today
(NASDAQ: ARCT)

Name: Arcturus Therapeutics Share Price Today (NASDAQ: ARCT) - Arcturus Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Arcturus Therapeutics share price is $16.05 & ₹1,395.85 as on 6 Mar 2025, 2.30 'hrs' IST

$16.05

▲

0.56

(3.62%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Arcturus Therapeutics share price in Dollar and Rupees. Guide to invest in Arcturus Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Arcturus Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Arcturus Therapeutics share price movements

Today's Low: $15.45
Today's High: $16.19
$16.05
3.74%
Downside
Day's Volatility :4.57%
Upside
0.86%
52 Weeks Low: $14.30
52 Weeks High: $45.00
$16.05
10.9%
Downside
52 Weeks Volatility :68.22%
Upside
64.33%

Arcturus Therapeutics (ARCT) Returns

Period	Arcturus Therapeutics Holdings Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-13.22%	2.1%	0.0%
6 Months	-17.69%	-4.1%	0.0%
1 Year	-59.0%	2.2%	0.0%
3 Years	-13.37%	11.8%	-11.6%

Arcturus Therapeutics (ARCT) Key Statistics

in dollars & INR

Previous Close	$15.49
Open	$15.61
Today's High	$16.19
Today's Low	$15.45
Market Capitalization	$419.6M
Today's Volume	$111.7K
52 Week High	$45.0
52 Week Low	$14.3
Revenue TTM	$160.4M
EBITDA	$-77.0M
Earnings Per Share (EPS)	$-2.33
Profit Margin	-39.05%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-23.12%

How to invest in Arcturus Therapeutics Stock (ARCT) from India?

It is very easy for Indian residents to invest directly in Arcturus Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Arcturus Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Arcturus Therapeutics or ARCT on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Arcturus Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Arcturus Therapeutics shares which would translate to 0.054 fractional shares of Arcturus Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Arcturus Therapeutics, in just a few clicks!

Returns in Arcturus Therapeutics (ARCT) for Indian investors in Rupees

The Arcturus Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Arcturus Therapeutics investment value today

Current value as on today

₹47,446

Returns

₹52,554

(-52.55%)

Returns from Arcturus Therapeutics Stock

₹57,517 (-57.52%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Arcturus Therapeutics (ARCT)

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Arcturus Therapeutics Stock from India on INDmoney has increased by 9% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Arcturus Therapeutics

Federated Hermes Inc
17.33%
BlackRock Inc
11.04%
Sumitomo Mitsui Trust Group Inc
7.62%
Nikko Asset Management Americas Inc
7.62%
ARK Investment Management LLC
7.14%
Vanguard Group Inc
6.22%

Analyst Recommendation on Arcturus Therapeutics

Buy

87%Buy

6%Hold

6%Sell

Based on 16 Wall street analysts offering stock ratings for Arcturus Therapeutics(by analysts ranked 0 to 5 stars)

Based on 16 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Arcturus Therapeutics Stock (ARCT)

What analysts predicted

Upside of 375.52%

Target:

$76.32

Current:

$16.05

Insights on Arcturus Therapeutics Stock (Ticker Symbol: ARCT)

Price Movement
In the last 1 year, ARCT stock has moved down by -58.8%
Decreasing Revenue
Revenue is down for the last 2 quarters, 45.97M → 38.81M (in $), with an average decrease of 15.6% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -26.81M → -6.90M (in $), with an average increase of 102.6% per quarter
ARCT vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 121.1%
ARCT vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 65.5%
Price to Sales
ForARCT every $1 of sales, investors are willing to pay $2.6, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

ARCT Arcturus Therapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$15.8M	↑ 21.2%
Net Income	$-21.8M	↑ 99.83%
Net Profit Margin	-138.29%	↓ 54.42%

	FY19	Y/Y Change
Revenue	$20.8M	↑ 31.97%
Net Income	$-25.7M	↑ 18.07%
Net Profit Margin	-123.72%	↑ 14.57%

	FY20	Y/Y Change
Revenue	$9.5M	↓ 54.12%
Net Income	$-71.4M	↑ 177.45%
Net Profit Margin	-748.13%	↓ 624.41%

	FY21	Y/Y Change
Revenue	$12.4M	↑ 29.56%
Net Income	$-206.9M	↑ 189.87%
Net Profit Margin	-1.7K%	↓ 925.65%

	FY22	Y/Y Change
Revenue	$205.8M	↑ 1564.82%
Net Income	$9.3M	↓ 104.52%
Net Profit Margin	4.54%	↑ 1678.32%

	FY23	Y/Y Change
Revenue	$157.7M	↓ 23.33%
Net Income	$-29.7M	↓ 417.95%
Net Profit Margin	-18.84%	↓ 23.38%

	Q2 FY23	Q/Q Change
Revenue	$9.6M	↓ 88.0%
Net Income	$-52.6M	↓ 203.54%
Net Profit Margin	-549.4%	↓ 613.06%

	Q3 FY23	Q/Q Change
Revenue	$43.4M	↑ 353.49%
Net Income	$-16.2M	↓ 69.13%
Net Profit Margin	-37.4%	↑ 512.0%

	Q4 FY23	Q/Q Change
Revenue	$28.2M	↓ 34.96%
Net Income	$-8.6M	↓ 47.15%
Net Profit Margin	-30.39%	↑ 7.01%

	Q1 FY24	Q/Q Change
Revenue	$32.6M	↑ 15.55%
Net Income	$-26.8M	↑ 212.81%
Net Profit Margin	-82.27%	↓ 51.88%

	Q2 FY24	Q/Q Change
Revenue	$46.0M	↑ 41.04%
Net Income	$-17.2M	↓ 35.8%
Net Profit Margin	-37.45%	↑ 44.82%

	Q3 FY24	Q/Q Change
Revenue	$38.8M	↓ 15.58%
Net Income	$-6.9M	↓ 59.9%
Net Profit Margin	-17.78%	↑ 19.67%

	FY18	Y/Y Change
Profit	$-1.2M	↓ 109.76%

	FY19	Y/Y Change
Profit	$-11.7M	↑ 848.01%

	FY20	Y/Y Change
Profit	$-46.4M	↑ 298.31%

	FY21	Y/Y Change
Profit	$-159.5M	↑ 243.7%

	FY22	Y/Y Change
Profit	$62.7M	↓ 139.31%

	FY23	Y/Y Change
Profit	$154.8M	↑ 146.86%

	Q2 FY23	Q/Q Change
Profit	$-43.1M	↓ 254.15%

	Q3 FY23	Q/Q Change
Profit	$42.6M	↓ 198.78%

	Q4 FY23	Q/Q Change
Profit	$27.4M	↓ 35.65%

	Q1 FY24	Q/Q Change
Profit	$38.0M	↑ 38.75%

	Q2 FY24	Q/Q Change
Profit	$45.1M	↑ 18.58%

	Q3 FY24	Q/Q Change
Profit	$41.7M	↓ 7.55%

	FY18	Y/Y Change
Operating Cash Flow	$-20.8M	↑ 4413.04%
Investing Cash Flow	$22.1M	↑ 113.75%
Financing Cash Flow	$10.2M	↑ 45.81%

	FY19	Y/Y Change
Operating Cash Flow	$-6.4M	↓ 68.95%
Investing Cash Flow	$-818.0K	↓ 103.7%
Financing Cash Flow	$41.9M	↑ 310.69%

	FY20	Y/Y Change
Operating Cash Flow	$-42.9M	↑ 565.03%
Investing Cash Flow	$-1.7M	↑ 112.96%
Financing Cash Flow	$436.1M	↑ 940.74%

	FY21	Y/Y Change
Operating Cash Flow	$-135.0M	↑ 215.07%
Investing Cash Flow	$-3.4M	↑ 95.52%
Financing Cash Flow	$48.0M	↓ 88.99%

	FY22	Y/Y Change
Operating Cash Flow	$32.0M	↓ 123.69%
Investing Cash Flow	$-7.7M	↑ 126.83%
Financing Cash Flow	$-2.9M	↓ 105.95%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$50.8M	↓ 241.64%
Investing Cash Flow	$-354.0K	↓ 48.77%
Financing Cash Flow	$94.0K	↓ 100.34%

Arcturus Therapeutics Technicals Summary

Sell

Neutral

Buy

Arcturus Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Arcturus Therapeutics (ARCT) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Arcturus Therapeutics Holdings Inc	-3.49%	-17.69%	-59.0%	-13.37%	6.68%
Regeneron Pharmaceuticals, Inc.	1.3%	-41.29%	-30.51%	9.2%	42.38%
Beone Medicines Ltd	15.19%	34.31%	61.3%	43.16%	68.1%
Vertex Pharmaceuticals Incorporated	3.37%	3.77%	18.06%	106.43%	121.36%
Alnylam Pharmaceuticals, Inc.	-11.52%	-3.4%	62.32%	49.04%	120.93%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Arcturus Therapeutics Holdings Inc	10.3	NA	NA	-2.38	-0.23	-0.12	NA	9.67
Regeneron Pharmaceuticals, Inc.	17.85	17.85	1.03	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.33	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Arcturus Therapeutics Holdings Inc	Buy	$419.6M	6.68%	10.3	-39.05%
Regeneron Pharmaceuticals, Inc.	Buy	$74.9B	42.38%	17.85	31.07%
Beone Medicines Ltd	NA	$28.5B	68.1%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.1B	121.36%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.5B	120.93%	NA	-12.37%

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Organization	Arcturus Therapeutics
Employees	180
CEO	Mr. Joseph E. Payne M.Sc.
Industry	Health Technology

Management People of Arcturus Therapeutics

Name	Title
Mr. Joseph E. Payne M.Sc.	Founder, President, CEO & Director
Dr. Padmanabh Chivukula Ph.D.	Founder, Chief Scientific Officer, COO & Secretary
Mr. Andrew H. Sassine MBA	CFO & Director
Mr. Lance Kurata	Chief Legal Officer
Ms. Neda Safarzadeh	Vice President and Head of IR/PR & Marketing
Ms. Natash O. Bowman	Chief Human Resources Officer
Mr. Kevin T. Skol	Chief Business Officer
Dr. Juergen Froehlich FCPh, M.D., MBA	Chief Medical Officer
Dr. Igor Smolenov M.D., Ph.D.	Chief Development Officer
Ms. Roberta Duncan	Chief Strategy Officer

Important FAQs about investing in ARCT Stock from India :

What is Arcturus Therapeutics share price today?

Arcturus Therapeutics share price today stands at $16.05, Open: $15.61 ; Previous Close: $15.49 ; High: $16.19 ; Low: $15.45 ; 52 Week High: $45.00 ; 52 Week Low: $14.30.

The stock opens at $15.61, after a previous close of $15.49. The stock reached a daily high of $16.19 and a low of $15.45, with a 52-week high of $45.00 and a 52-week low of $14.30.

Can Indians buy Arcturus Therapeutics shares?

Yes, Indians can invest in the Arcturus Therapeutics (ARCT) from India.

With INDmoney, you can buy Arcturus Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Arcturus Therapeutics at zero transaction cost.

How can I buy Arcturus Therapeutics shares from India?

It is very easy to buy Arcturus Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Arcturus Therapeutics (ARCT) be purchased?

Yes, you can buy fractional shares of Arcturus Therapeutics with INDmoney app.

What are the documents required to start investing in Arcturus Therapeutics stocks?

To start investing in Arcturus Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.